Anti-SARS-CoV-2 antibody

Abstract

To provide antibodies that bind to N-protein of SARS-CoV-2 and use methods thereof.SOLUTION: Disclosed is a SARS-CoV-2-binding antibody that comprises one or more structural domains comprising CDRs shown in the following (a) or (b); (a) CDR1 comprising an amino acid sequence of SEQ ID NO:1 or an amino acid sequence where one amino acid substituted by another amino acid in the amino acid sequence of SEQ ID NO:1; CDR2 comprising an amino acid sequence of SEQ ID NO:2 or an amino acid sequence where one amino acid substituted by another amino acid in the amino acid sequence of SEQ ID NO:2; CDR3 comprising an amino acid sequence of SEQ ID NO:3 or an amino acid sequence where one amino acid substituted by another amino acid in the amino acid sequence of SEQ ID NO:3, or (b) CDR1 comprising an amino acid sequence of SEQ ID NO:4 or an amino acid sequence where one amino acid substituted by another amino acid in the amino acid sequence of SEQ ID NO:4; CDR2 comprising an amino acid sequence of SEQ ID NO:5 or an amino acid sequence where one amino acid substituted by another amino acid in the amino acid sequence of SEQ ID NO:5; CDR3 comprising an amino acid sequence of SEQ ID NO:6 or an amino acid sequence where one amino acid substituted by another amino acid in the amino acid sequence of SEQ ID NO:6.SELECTED DRAWING: None

Claims

1. A VHH antibody, a heavy chain antibody, or a polymer of the VHH antibody that binds to the N-protein of SARS-CoV-2, having one or more structural domains containing the CDR shown in (a) or (b) below. (a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 1, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3 (b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 4, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 5, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 6

2. The antibody according to claim 1, wherein the VHH antibody polymer is a polymer formed by linking multiple structural domains.

3. The antibody according to claim 1, wherein the VHH antibody polymer is a polymer formed by linking one or more of the structural domains with one or more structural domains having different antigen specificity from the said structural domains.

4. A nucleic acid encoding the antibody according to claim 1.

5. A method for detecting SARS-CoV-2 in a sample, comprising the step of contacting a test sample with a VHH antibody, a heavy chain antibody, or a polymer of the VHH antibody that binds to the N-protein of SARS-CoV-2 and has one or more structural domains containing a CDR as shown in (a) or (b) below. (a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 1, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3 (b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 4, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 5, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 6

6. A SARS-CoV-2 detection kit containing the antibody according to any one of claims 1 to 3.

7. A pharmaceutical product containing the antibody described in any one of claims 1 to 3.

8. The pharmaceutical agent according to claim 7 for the prevention or treatment of SARS-CoV-2 infection.

Images